BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

@article{Gavriatopoulou2017BDRIN,
  title={BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.},
  author={Maria Gavriatopoulou and Ram{\'o}n Garc{\'i}a-Sanz and Efstathios Kastritis and Pierre Morel and Marie-Christine Kyrtsonis and Eurydiki Michalis and Zafiris Kartasis and Xavier Leleu and Giovanni Palladini and Alessandra Tedeschi and Dimitra Gika and Giampaolo Merlini and P. Sonneveld and Meletios Athanasios Dimopoulos},
  journal={Blood},
  year={2017},
  volume={129 4},
  pages={456-459}
}
In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untreated symptomatic patients with Waldenström macroglobulinemia (WM), most of which were of advanced age and with adverse prognostic factors. BDR consisted of a single 21-day cycle of bortezomib alone (1.3 mg/m2 IV on days 1, 4, 8, and 11), followed by weekly IV bortezomib (1.6 mg/m2 on days 1, 8, 15, and 22) for 4 additional 35-day cycles, with IV… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 21 times over the past 90 days. VIEW TWEETS